Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Drugs that combat aging may be available within five years, following landmark work led by an Australian researcher. The work, published in the March 8 issue of Science, finally proves that a single anti-aging enzyme in the body can be targeted, with the potential to prevent age-related diseases and extend lifespans. 9 March 2013
Biotechnology
UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application for albiglutide, with the proprietary name Eperzan, to the European Medicines Agency. Albiglutide is an investigational once-weekly treatment for adult patients with type 2 diabetes which is not yet approved anywhere in the world. A filing with the US Food and Drug Administration was made earlier this year (The Pharma Letter January 15). 7 March 2013
Pharmaceutical
Danish insulin giant Novo Nordisk (NOVN: N) has started the European roll-out of its Tresiba (insulin degludec), a new once-daily basal insulin for adult patients with type 1 and type 2 diabetes, starting with the UK and Denmark on March 4. Further European launches are expected through the rest of this year and 2014. 4 March 2013
Biotechnology
In an early benefit assessment under Germany's Act on the Reform of the Market for Medicinal Products (AMNOG), the Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether the fixed combination of the drugs saxagliptin and metformin, marketed by US drugmaker Bristol-Myers Squibb (NYSE: BMY) and Anglo-Swedish pharma firm AstraZeneca (LSE: ANZ) as Komboglyze and Onglyza, offers an added benefit versus the current standard treatment for diabetes. The agency also examined Cell Therapeutics' (Nasdaq: CTIC) non-Hodgkin lymphomas treatment Pixuvri (pixantrone). 4 March 2013
Pharmaceutical
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report. 26 February 2013
Biotechnology
US drug developer Lexicon Pharmaceutical (Nasdaq: LXRX) yesterday updated its drug development pipeline, highlighting progress with its LX4211, telotristat etiprate and other drug candidates. 21 February 2013
Pharmaceutical
The US Food and Drug Administration has accepted for review French drug major Sanofi's (Euronext: SAN) New Drug Application for lixisenatide, the first once-daily prandial GLP-1 receptor agonist for the treatment of adults with type 2 diabetes mellitus, the company announced this morning. 19 February 2013
Biotechnology
US generic drugmaker Mylan (Nasdaq: MYL) said yesterday that it has entered into a definitive agreement with Indian biopharma company Biocon for an exclusive strategic collaboration on the development and commercialization of generic versions of three insulin analog products. 14 February 2013
Pharmaceutical
Danish insulin giant Novo Nordisk (NOV: N) yesterday announced that it has received approval of the price of Tresiba (insulin degludec), the new once-daily basal insulin for the treatment of type 1 and type 2 diabetes, from Japan's Central Social Insurance Medical Council (Chuikyo), the advisory committee to the Minister of Health, Labor and Welfare. 13 February 2013
Pharmaceutical
Danish insulin giant Novo Nordisk (NOV: N) revealed late Sunday that, on February 8, it received a Complete Response Letter from the US Food and Drug Administration regarding the New Drug Applications for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart), saying the FDA requires more data before it can consider approval of the company's new type 2 diabetes products. Novo Nordisk's shares slumped 15.5% to 905 Danish kroner in early trading this morning. 11 February 2013
Pharmaceutical
French drug major Sanofi (Euronext: SAN) this morning announced that the European Commission has granted Marketing Authorization for Lyxumia its (lixisenatide). Lyxumia the first once-daily prandial GLP-1 receptor agonist, is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycemic control. 4 February 2013
Pharmaceutical
UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has published draft guidance today (February 1) on the use of Swiss drug major Roche's (ROG: SIX) Avastin (bevacizumab) for treating advanced ovarian cancer that has returned six months or more after initial treatment with platinum-based chemotherapy (platinum-sensitive disease). 1 February 2013
Pharmaceutical
In what was a busy news day for the US Food and Drug Administration, the agency on Friday approved three new related products from Japan's largest drugmaker, Takeda Pharmaceuticals (TYO: 4502), for use with diet and exercise to improve blood sugar control in adults with type 2 diabetes: Nesina (alogliptin), Kazano (alogliptin and metformin hydrochloride) and Oseni (alogliptin and pioglitazone) tablets. 28 January 2013
Pharmaceutical
Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five years, both production and demand will continue to grow, according to a new report added to the offering of companiesandmarkets.com. 24 January 2013
Pharmaceutical
Following positive recommendations from the European Medicines Agency's advisory committee, the European Medicines Agency's Committee for Medicinal Products for Human (The Pharma Letter October 22, 2012), late yesterday Danish insulin giant Novo Nordisk (NOVN: N) announced that the European Commission has granted marketing authorizations for its once-daily Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) for the treatment of diabetes in adults. The authorizations cover all 27 European Union member states. 22 January 2013
Pharmaceutical
Confirming expectations announced when Pfizer (NYSE: PFE) revealed its $680 million acquisition of NextWave Pharmaceuticals (The Pharma Letter October 23, 2012), the US drugs behemoth said that Quillivant XR (methylphenidate hydrochloride) CII for extended-release oral suspension is now available in the USA for the treatment of attention deficit hyperactivity disorder (ADHD). Quillivant XR, NextWave's lead product, is the first once-daily, extended-release liquid methylphenidate for ADHD and is now available by prescription. 15 January 2013
Pharmaceutical
Anglo-Swedish drug major AstraZeneca (LSE: AZN) and partner Bristol-Myers Squibb (NYSE: BMY) of the USA says that the Scottish Medicines Consortium (SMC) yesterday approved the National Health Service Boards to give physicians the go-ahead to prescribe Forxiga (dapagliflozin) to adults in Scotland with type 2 diabetes for restricted use as dual therapy in combination with metformin, when metformin alone with diet and exercise does not provide adequate glycemic control and a sulphonylurea is inappropriate. 14 January 2013
Pharmaceutical
The US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee yesterday voted 10 to five to recommend approval health care giant Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development's canagliflozin, proposed trade name Invokana, to treat type 2 diabetes in adult patients based on the efficacy and safety results from its comprehensive clinical development program. If it gains final approval from the FDA, Invokana would be the first in a new class medicines known as SGLT2 inhibitors. 11 January 2013
Pharmaceutical
US drug major Eli Lilly (NYSE: LLY) and German independent drugmaker Boehringer Ingelheim said yesterday that they will adjust the scope of their diabetes alliance with respect to LY2605541, Lilly's novel basal insulin analog, with the US firm reassuming sole worldwide development and commercialization rights to the compound. 8 January 2013
Biotechnology
German biotech firm Evotec (EVT: TecDAX) has acquired all the shares in Cell Culture Service GmbH (CCS), a Hamburg-based company which supports the cell culture needs of a worldwide customer base of biotech and pharmaceutical companies. 7 January 2013
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze